Zeiss Receives FDA Approval of the CT Lucia 621P Monofocal IOL

Zeiss announced that the FDA has approved the CT Lucia 621P monofocal IOL, an aspheric, monofocal, single-piece C-loop IOL.

The IOL features the patented Zeiss Optic (ZO) Asphericity Concept, which is designed to compensate for a wide range of spherical aberrations and at the same time optimize visual outcomes in the event of potential decentration and lens misalignments. The IOL comes in a fully preloaded injector for a smooth and controlled injection, and the architecture of the IOL is designed to enable easy centering while maximizing direct capsular contact, thus ensuring stability and supporting a consistent position in the bag, according to Zeiss.

“Even in a standard case where everything goes well, we may see short and/or long-term decentration because each eye is anatomically a little different. What is great about the Zeiss Optic is it combines advantageous qualities of both aspheric and spherical lenses, making the lens design less susceptible to optical decentration issues even up to a millimeter, thus helping to maintain optical quality. Zeiss has a brand built on high quality optics like this,” William Wiley, MD, Medical Director of the Cleveland Eye Clinic (USA), said in a company news release.